Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information
- 1 April 2014
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 27 (4), 554-561
- https://doi.org/10.1038/modpathol.2013.153
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast CancerCancer Investigation, 2010
- Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet?International Journal of Surgical Pathology, 2008
- Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signaturesBreast Cancer Research, 2008
- Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node–Negative CohortClinical Cancer Research, 2008
- Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving TherapyJournal of Clinical Oncology, 2008
- Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?Human Pathology, 2008
- A risk index for early node-negative breast cancerBritish Journal of Surgery, 2006
- p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomasVirchows Archiv, 2005
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005